**9.** Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: A randomized trial. Eur J Prev Cardiol. 2015; 22(3): 389–396. doi:10.1177/2047487313518479.
**10.** Papakatsika S, Stabouli S, Antza C, Kotsis V. Early Vascular Aging: A New Target for Hypertension Treatment. Curr Pharm Des. 2015; 22(1): 122–126. doi: 10.2174/1381612822666151109112813.
**11.** Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: A meta-analysis of individual data in 294 patients. J Hypertens. 2011; 29(6): 1034–1042. doi: 10.1097/HJH.0b013e328346a583.
**12.** Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006; 48(1): 80–86. doi: 10.1161/01.HYP.0000224283.76347.8c.
**13.** Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013; 26(5): 608–616. doi:10.1093/ajh/hps098.
**14.** Meng X, Qie L, Wang Y, Zhong M, Li L. Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity. Clin Investig Med. 2009; 32(6): 238–243.
**15.** Ballard KD, Taylor BA, Capizzi JA, Grimaldi AS, White CM, Thompson PD. Atorvastatin Treatment Does Not Alter Pulse Wave Velocity in Healthy Adults. Int Sch Res Not. 2014; 2014: 1–5. doi: 10.1155/2014/239575.
**16.** Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014; 64(21): 2207–2217.
**17.** Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643–2653. doi: 10.1056/NEJMoa052187.
**18.** Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–1589. doi: 10.1056/NEJMoa0806470.
**19.** Simes J, Simes RJ, Hunt D, et al. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet. 2002; 359(9315): 1379–1387. doi: 10.1016/S0140-6736(02)08351-4.
**20.** Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. 2011; 32(20): 2525–2532. doi: 10.1093/eurheartj/ehr333.
**21.** Bosch J, Lonn E, Pogue J, Arnold JMO, Dagenais GR, Yusuf S. Long-term effects of Ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation. 2005; 112(9): 1339–1346. doi: 10.1161/CIRCULATIONAHA.105.548461.
**22.** Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure--lowering and lipid-lowering treatment in patients with hypertension in the Anglo--Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137. doi: 10.1016/S0140-6736(18)31776-8.
**23.** Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016; 388: 2665–2712.

E-SHOP SOLEN MEDICAL EDUCATION 20 let s vámi

Vydáváme knihy oceňované odbornými lékařskými společnostmi

Prohlédněte si **ukázky publikací** dostupných v našem e-shopu na **www.solen.cz**

Cena děkana LF UP za významnou publikační činnost za rok 2013 v kategorii monografie a 2. místo v literární soutěži České internistické společnosti.

Cena České onkologické společnosti za nejlepší knižní publikaci 2017 a také 1. místo v soutěži České urologické společnosti o nejlepší vědeckou publikaci za rok 2017 v kategorii „Monografie nebo postgraduální učební text“.

Aktuální NOVINKA: